The limited number of significant dysregulated genes in BOS (only 2 out of 40) compared to AML-ASXL1 (18 out of 40) may reflect the inherent limitations of a smaller sample size associated with BOS, a rare disease. The gene discussed is ASXL1; the disease is acute myeloid leukemia.